The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 2, 2012, Pages 221-230

  Bartscht, Tobias ^a   Lehnert, Hendrik ^a   Gieseler, Frank ^a   Ungefroren, Hendrik ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ALK5; PP1; PP2; Src; SU6656; TGF

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; GELATINASE A; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SRC-FAMILY KINASES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84866530179     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1904-0     Document Type: Article

References (29)

1. Gaspar NJ, Li L, Kapoun AM et al (2007) Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol 72:152-161
2. Zu X, Zhang Q, Cao R et al (2012) Transforming growth factor-b signaling in tumor initiation, progression and therapy in breast cancer: An update. Cell Tissue Res 347:73-84
3. Jeon HS, Jen J (2010) TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol 5:417-419
4. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806
5. Calorini L, Bianchini F (2010) Environmental control of invasiveness and metastatic dissemination of tumor cells: The role of tumor cell-host cell interactions. Cell Commun Signal 8:24
6. Friess H, Yamanaka Y, Buchler M et al (1993) Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105:1846-1856
7. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-b family signalling. Nature 425:577-584
8. Schniewind B, Groth S, Sebens Muerkoster S et al (2007) Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene 26:4850-4862
9. Melisi D, Ishiyama S, Sclabas GM et al (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829-840
10. Wendt MK, Tian M, Schiemann WP (2012) Deconstructing the mechanisms and consequences of TGF-b-induced EMT during cancer progression. Cell Tissue Res 347:85-101
11. Giampieri S, Pinner S, Sahai E (2010) Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res 70:3435-3439
12. Bra'bek J, Mierke CT, Rosel D et al (2010) The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal 8:22
13. Ellenrieder V, Hendler SF, Ruhland C et al (2001) TGF-betainduced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93:204-211
14. Kim LC, Song L, Haura EB (2009) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587-595
15. Nagaraj NS, Datta PK (2010) Targeting the transforming growth factor-b signaling pathway in human cancer. Expert Opin Investig Drugs 19:77-91
16. Maeda M, Shintani Y, Wheelock MJ, Johnson KR (2006) Src activation is not necessary for Transforming growth factor (TGF)-b-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II. J Biol Chem 281:59-68
17. Ungefroren H, Sebens S, Groth S et al (2011) The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors. Curr Cancer Drug Targets 11:524-535
18. Medicherla S, Li L, Ma JY et al (2007) Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res 27:4149-4157
19. Keese CR, Bhawe K, Wegener J et al (2002) Real-time impedance assay to follow the invasive activities of metastatic cells in culture. Biotechniques 33:842-844, 846, 848-850
20. Atienza JM, Yu N, Kirstein SL et al (2006) Dynamic and labelfree cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev Technol 4:597-607
21. Blake RA, Broome MA, Liu X et al (2000) SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20:9018-9027
22. Inman GJ, Nicolas FJ, Callahan JF et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-b superfamily type I receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74
23. Groth S, Schulze M, Kalthoff H et al (2005) Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem 280:33190-33199
24. Chen HC (2005) Cell-scatter assay. Methods Mol Biol 294:69-77
25. Wieser R, Wrana JL, Massagué J (1995) GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J 14: 2199-2208
26. Ungefroren H, Sebens S, Groth S et al (2011) Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells. Int J Oncol 38:797-805
27. Ito H, Gardner-Thorpe J, Zinner MJ et al (2003) Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134:221-226
28. Duxbury MS, Ito H, Zinner MJ et al (2004) Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10:2307-2318
29. Ischenko I, Camaj P, Seeliger H (2008) Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: An involvement of epidermal growth factor receptor signaling. Oncogene 27:7212-7222